| Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). | |
| | |
MedLine Citation:
|
PMID: 21094359 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Plasma levels of high-sensitivity C-reactive protein (hsCRP) are an important predictor of cardiovascular disease, and achievement of lower targets of hsCRP with rosuvastatin treatment was associated with improved cardiovascular outcomes. The aim of this study was to examine whether hsCRP levels were related to genetic variants and traditional cardiovascular risk factors in Chinese patients treated with rosuvastatin 10 mg/day. The relations were analyzed between on-treatment plasma hsCRP concentrations and cardiovascular risk factors and 14 single-nucleotide polymorphisms in CRP and other candidate genes. In 281 patients with a median plasma hsCRP level of 0.81 mg/L (interquartile range 0.46 to 1.86), higher hsCRP levels were significantly associated with female gender, greater waist circumference (WC), having diabetes, higher triglycerides, and lower high-density lipoprotein (HDL) cholesterol. Three single-nucleotide polymorphisms (rs1205, 3872G>A and rs2808630, 5237A>G in CRP and rs1169288, I27L in HNF1A) were independently associated with hsCRP levels before and after adjustment for other variables. WC and the CRP rs1205 polymorphism showed the strongest relations with hsCRP, and in multiple regression analysis, gender, WC, diabetes, triglycerides, HDL cholesterol, and the 3 genetic variants explained 35.5% of the variance in hsCRP levels. The 2 CRP polymorphisms, female gender, higher WC, and lower HDL cholesterol were associated with risk for having CRP concentrations ≥ 1 mg/L. In conclusion, central obesity, low HDL cholesterol, and CRP polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with rosuvastatin. |
| | |
Authors:
|
Miao Hu; Michael H K Lee; Valiant W L Mak; Brian Tomlinson |
Related Documents
:
|
3902379 - Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoprot... 3310569 - Double-blind trial of the long-term effects of acebutolol and propranolol on serum lipo... 6177959 - The emerging problem of plasma lipid changes during antihypertensive therapy. 14624689 - Following severe injury, hypocholesterolemia improves with convalescence but persists w... 7355139 - Cholesterol, triglyceride, and lipoprotein studies: strategies for clinical use. 17193899 - Effect of smoking on lipid profile and lipid peroxidation in normal subjects. 2178479 - The effects of ethanol consumption on the expression of immunity to trichinella spirali... 9250529 - Digestibility, apparent mineral absorption, and voluntary intake by horses fed alfalfa,... 11478319 - Orotic acid, a new promoter for experimental liver carcinogenesis. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 106 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2011-01-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1588-93 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged C-Reactive Protein / genetics*, metabolism China / epidemiology Cholesterol, HDL / blood* Coronary Disease / epidemiology, genetics*, prevention & control DNA / genetics* Dose-Response Relationship, Drug Female Fluorobenzenes / administration & dosage* Genotype Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage Incidence Male Middle Aged Nephelometry and Turbidimetry Obesity, Abdominal / blood*, complications, genetics Polymorphism, Genetic* Pyrimidines / administration & dosage* Risk Factors Sulfonamides / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin; 9007-41-4/C-Reactive Protein; 9007-49-2/DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electrocardiograms of menopausal women with coronary heart disease or at increased risk for its occu...
Next Document: Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.